Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 3/2018

01-07-2018 | Original Article

Genotype phenotype correlation in Asian Indian von Hippel–Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma

Authors: Nilesh Lomte, Sanjeet Kumar, Vijaya Sarathi, Reshma Pandit, Manjunath Goroshi, Swati Jadhav, Anurag R. Lila, Tushar Bandgar, Nalini S. Shah

Published in: Familial Cancer | Issue 3/2018

Login to get access

Abstract

The data in genotype-phenotype correlation in Indian von Hippel–Lindau (VHL) patients is limited. We have retrospectively studied 31 genetically proven VHL patients with pheochromocytoma/paraganglioma (PCC/PGL) from families and have reviewed the World literature on PCC/PGL in patients with large VHL deletions. Three patients had large deletions and 28 patients had other mutations [missense mutations in 25, 3 bp deletion in 2 and single bp duplication in one]. Unilateral PCC were significantly more common in patients with large VHL deletions whereas multiple PCC (bilateral PCC or PCC + sympathetic PGL) were significantly more common in those with other mutations. World literature review confirmed the rarity of PCC/PGL in patients with large deletions and we report the first definitive case of PCC associated with complete VHL deletion. Pancreatic neuroendocrine tumours were more common, often metastatic and the most common cause of death in our cohort. Our study had eight parent off-spring pairs from five families. The off-springs were significantly younger at presentation and had significantly higher number of PCC/PGL. In conclusion, PCC/PGL are rare in patients with large VHL deletions and if occur are most likely to be solitary. Patients with bilateral PCC or multifocal PCC/PGL are least likely to have large VHL deletions. Our study also provides additional evidence for existence of the phenomenon of anticipation in VHL syndrome.
Literature
1.
2.
Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER (2007) Genotype–phenotype correlations in von Hippel–Lindau disease. Hum Mutat 28(2):143–149CrossRefPubMed
3.
Maher ER, Yates JR, Harries R et al (1990) Clinical features and natural history of von Hippel–Lindau disease. Q J Med 77(283):1151–1163CrossRefPubMed
4.
Gläsker S, Neumann HPH, Koch CA, Vortmeyer AO (2000) Von Hippel–Lindau Disease. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A (eds) Endotext [Internet]. MDText.com, Inc., South Dartmouth, MA
5.
6.
Gossage L, Eisen T, Maher ER (2015) VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15(1):55–64CrossRefPubMed
7.
McNeill A, Rattenberry E, Barber R, Killick P, MacDonald F, Maher ER (2009) Genotype–phenotype correlations in VHL exon deletions. Am J Med Genet A 149A(10):2147–2151CrossRefPubMed
8.
Pandit R, Khadilkar K, Sarathi V, Kasaliwal R et al (2016) Germline mutations and genotype–phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma. Eur J Endocrinol 175(4):311–323CrossRefPubMed
9.
Vikkath N, Valiyaveedan S, Nampoothiri S et al (2015) Genotype–phenotype analysis of von Hippel–Lindau syndrome in fifteen Indian families. Fam Cancer 14(4):585–594CrossRefPubMed
10.
Ebenazer A, Rajaratnam S, Pai R et al (2013) Detection of large deletions in the VHL gene using a real–time PCR with SYBR green. Fam Cancer 12(3):519–524CrossRefPubMed
11.
12.
13.
Schwarz JM, Cooper DN, Schuelke M et al (2014) MutationTaster2: mutation prediction for the deep–sequencing age. Nat Methods 11:361–362CrossRefPubMed
14.
15.
Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081CrossRefPubMed
16.
Stenson PD, Mort M, Ball EV et al (2014) The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 133:1–9CrossRefPubMed
17.
18.
Gossage L, Pires DE, Olivera–Nappa Á (2014) An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma. Hum Mol Genet 15(22):5976–5988CrossRef
19.
Nordstrom–O’Brien M, van der Luijt RB, van Rooijen E et al (2010) Genetic analysis of von Hippel–Lindau disease. Hum Mutat 31(5):521–537PubMed
20.
Wong M, Chu YH, Tan HL et al (2016) Clinical and molecular characteristics of East Asian patients with von Hippel–Lindau syndrome. Chin J Cancer 35:79CrossRefPubMedPubMedCentral
21.
Crossey PA, Richards FM, Foster K, Green JS et al (1994) Identification of intragenic mutations in the von Hippel–Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 3(8):1303–1308CrossRefPubMed
22.
Chen F, Kishida T, Yao M, Hustad T, Glavac D et al (1995) Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5(1):66–75CrossRefPubMed
23.
Franke G, Bausch B, Hoffmann MM et al (2009) Alu Alu recombination underlies the vast majority of large VHL germline deletions: Molecularcharacterization and genotype–phenotype correlations in VHL patients. Hum Mutat 30(5):776–786CrossRefPubMed
24.
Hes F, Zewald R, Peeters T, Sijmons R et al (2000) Genotype–phenotype correlations in families with deletions in the von Hippel–Lindau (VHL) gene. Hum Genet 106(4):425–431CrossRefPubMed
25.
Cybulski C, Krzystolik K, Murgia A, Górski B, Debniak T et al (2002) Germline mutations in the von Hippel–Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. J Med Genet 39(7):E38CrossRefPubMedPubMedCentral
26.
Rocha JC, Silva RL, Mendonça BB, Marui S et al (2003) High frequency of novel germline mutations in the VHL gene in the heterogeneous population of Brazil. J Med Genet 40(3):e31CrossRefPubMedPubMedCentral
27.
Maranchie JK, Afonso A, Albert PS, Kalyandrug S et al (2004) Solid renal tumor severity in von Hippel–Lindau disease is related to germline deletion length and location. Hum Mutat 23(1):40–46CrossRefPubMed
28.
Hes FJ, van der Luijt RB, Janssen AL et al (2007) Frequency of Von Hippel–Lindau germline mutations in classic and non–classic Von Hippel–Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation–dependent probe amplification. Clin Genet 72(2):122–129CrossRefPubMed
29.
Cascón A, Escobar B, Montero–Conde C et al (2007) Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel–Lindau patients. Hum Mutat 28(6):613–621CrossRefPubMed
30.
Huang JS, Huang CJ, Chen SK, Chien CC (2007) Associations between VHL genotype and clinical phenotype in familial von Hippel–Lindau disease. Eur J Clin Invest 37(6):492–500CrossRefPubMed
31.
Cho HJ, Ki CS, Kim JW (2009) Improved detection of germline mutations in Korean VHL patients by multiple ligation–dependent probe amplification analysis. J Korean Med Sci 24(1):77–83CrossRefPubMedPubMedCentral
32.
Gergics P, Patocs A, Toth M, Igaz P, Szucs N, Liko I et al (2009) Germline VHL gene mutations in Hungarian families with von Hippel–Lindau disease and patients with apparently sporadic unilateral pheochromocytomas. Eur J Endocrinol 161(3):495–502CrossRefPubMed
33.
Gomy I, Molfetta GA, de Andrade Barreto E et al (2010) Clinical and molecular characterization of Brazilian families with von Hippel–Lindau disease: a need for delineating genotype–phenotype correlation. Fam Cancer 9(4):635–642CrossRefPubMed
34.
Wu P, Zhang N, Wang X, Ning X, Li T, Bu D et al (2012) Family history of von Hippel–Lindau disease was uncommon in Chinese patients: suggesting the higher frequency of de novo mutations in VHL gene in these patients. J Hum Genet 57(4):238–243CrossRefPubMed
35.
Wang X, Zhang N, Ning X, Li T, Wu P, Peng S et al (2014) Higher prevalence of novel mutations in VHL gene in Chinese Von Hippel–Lindau disease patients. Urology 83(3):675-e1CrossRef
36.
37.
Kruizinga RC, Sluiter WJ, de Vries EG, Zonnenberg BA, Lips CJ et al (2013) Calculating optimal surveillance for detection of von Hippel–Lindau–related manifestations. Endocr Relat Cancer 21(1):63–71CrossRefPubMed
38.
Wittström E, Nordling M, Andréasson S (2014) Genotype–phenotype correlations, and retinal function and structure in von Hippel–Lindau disease. Ophthalmic Genet 35(2):91–106CrossRefPubMed
39.
Krzystolik K, Jakubowska A, Gronwald J et al (2014) Large deletion causing von Hippel–Lindau disease and hereditary breast cancer syndrome. Hered Cancer Clin Pract 12(1):16CrossRefPubMedPubMedCentral
40.
Ning XH, Zhang N, Li T, Wu PJ, Wang X, Li XY et al (2014) Telomere shortening is associated with genetic anticipation in Chinese Von Hippel–Lindaudisease families. Cancer Res 74(14):3802–3809CrossRefPubMed
41.
Lee JS, Lee JH, Lee KE, Kim JH, Hong JM, Ra EK et al (2016) Genotype–phenotype analysis of von Hippel–Lindau syndrome in Korean families: HIFα bindingsite missense mutations elevate age–specific risk for CNS hemangioblastoma. BMC Med Genet 17(1):48CrossRefPubMedPubMedCentral
42.
43.
Igarashi H, Ito T, Nishimori I et al (2014) Pancreatic involvement in Japanese patients with von Hippel–Lindau disease: results of a nationwide survey. J Gastroenterol 49(3):511–516CrossRefPubMed
44.
Binkovitz LA, Johnson CD, Stephens DH (1990) Islet cell tumors in von Hippel–Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. AJR Am J Roentgenol 155(3):501–505CrossRefPubMed
45.
Charlesworth M, Verbeke CS, Falk GA et al (2012) Pancreatic lesions in von Hippel–Lindau disease? A systematic review and meta–synthesis of the literature. J Gastrointest Surg 16(7):1422–1428CrossRefPubMed
46.
Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF et al (2007) Clinical, genetic and radiographic analysis of 108 patients with von Hippel–Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 142(6):814–818CrossRefPubMed
47.
Richards FM, Payne SJ, Zbar B, Affara NA et al (1995) Molecular analysis of de novo germline mutations in the von Hippel–Lindau disease gene. Hum Mol Genet 4(11):2139–2143CrossRefPubMed
48.
Oberlé I, Rousseau F, Heitz D, Kretz C, Devys D et al (1991) Instability of a 550 bp DNA segment and abnormal methylation in fragile X syndrome. Science 252(5009):1097–1102CrossRefPubMed
49.
La Spada AR, Wilson EM, Lubahn DB et al (1991) Androgen receptor gene mutations in X–linked spinal and bulbar muscular atrophy. Nature 352(6330):77–79CrossRefPubMed
50.
Mahadevan M, Tsilfidis C, Sabourin L, Shutler G et al (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science 255(5049):1253–1255CrossRefPubMed
51.
Ranen NG, Stine OC, Abbott MH et al (1995) Anticipation and instability of IT–15 (CAG)n repeats in parent–offspring pairs with Huntington disease. Am J Hum Genet 57(3):593–602PubMedPubMedCentral
52.
Tabori U, Nanda S, Druker H, Lees J, Malkin D (2007) Younger age of cancer initiation is associated with shorter telomere length in Li–Fraumeni syndrome. Cancer Res 67(4):1415–1418CrossRefPubMed
53.
Martinez–Delgado B, Yanowsky K, Inglada–Perez L et al (2011) Genetic anticipation is associated with telomere shortening in hereditary breast cancer. PLoS Genet 7(7):e1002182CrossRefPubMedPubMedCentral
54.
55.
Nilbert M, Timshel S, Bernstein I, Larsen K (2009) Role for genetic anticipation in Lynch syndrome. J Clin Oncol 27(3):360–364CrossRefPubMed
Metadata
Title
Genotype phenotype correlation in Asian Indian von Hippel–Lindau (VHL) syndrome patients with pheochromocytoma/paraganglioma
Authors
Nilesh Lomte
Sanjeet Kumar
Vijaya Sarathi
Reshma Pandit
Manjunath Goroshi
Swati Jadhav
Anurag R. Lila
Tushar Bandgar
Nalini S. Shah
Publication date
01-07-2018
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-0058-y

Other articles of this Issue 3/2018

Familial Cancer 3/2018 Go to the issue

Original Article

Screening for germline mutations in mismatch repair genes in patients with Lynch syndrome by next generation sequencing

Short Communication

Penetrance of a rare familial mutation predisposing to papillary thyroid cancer

Review

Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge

Original Article

Universal determination of microsatellite instability using BAT26 as a single marker in an Argentine colorectal cancer cohort

Correction

Corrections to: Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries

Letter to the Editor

Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits